Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 5/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.32 |
| ▸ | BRD2 | P25440 | 1/20 | 0.32 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.32 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452346 | 1.00 | BRD4 (0.39) | BRD4NPC1MAPTLMNAPDE10A | |
| SCHEMBL3452342 | 1.00 | BRD4 (0.39) | BRD4NPC1MAPTLMNAPDE10A | |
| SCHEMBL11886698 | 0.90 | SYK (0.38) | BRD4NPC1 | |
| SCHEMBL3854400 | 0.89 | BRD4 (0.38) | BRD4NPC1PDE10AKLKB1BRD2 | |
| SCHEMBL1054887 | 0.85 | BRD4 (0.35) | BRD4NPC1LMNABRD2BRD3 | |
| SCHEMBL1054889 | 0.85 | BRD4 (0.35) | BRD4NPC1LMNABRD2BRD3 | |
| SCHEMBL1054884 | 0.85 | BRD4 (0.38) | BRD4NPC1MAPTLMNAPDE10A | |
| SCHEMBL5506152 | 0.83 | BRD4 (0.46) | BRD4NPC1PDE10ARAB9APOLB | |
| SCHEMBL1929365 | 0.83 | BRD4 (0.46) | BRD4NPC1PDE10ARAB9APOLB | |
| SCHEMBL3848615 | 0.81 | TLR8 (0.39) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-07-26 | — | — | US | disclosed |
| US-7820646-B2 | Cyclized derivatives as Eg-5 inhibitors | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2106399-A2 | IMIDAZOLE DERIVATIVES AS KINESIN SPINDLE PROTEIN INHIBITORS (EG-5) | Novartis AG (CH) | 2009-10-07 | — | — | EP | disclosed |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | NOVARTIS AG | 2008-08-28 | — | — | US | disclosed |
| WO-2008086122-A2 | IMIDAZOLE DERIVATIVES AS KINESIN SPINDLE PROTEIN INHIBITORS (EG-5) | NOVARTIS AG (CH) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120189623-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | BRD4 2965/4885NPC1 191/4885MAPT 2116/4885 |
| US-20080207589-A1 | CYCLIZED DERIVATIVES AS EG-5 INHIBITORS | CYP3A5, GDI2, HDAC5 | BRD4 2965/4885NPC1 191/4885MAPT 2116/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.